The Two-Faced NF-κB in the Skin

REFERENCES

• Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431–6
   PubMed Web of Science ®Google Scholar
• Bonizzi G., Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends. Immunol. 2004; 25: 280–8
   PubMed Web of Science ®Google Scholar
• Koster M. I., Roop D. R. Mechanisms regulating epithelial stratification. Annu. Rev. Cell. Dev. Biol. 2007; 23: 93–113
   PubMed Web of Science ®Google Scholar
• Hu Y., Baud V., Oga T., Kim K. I., Yoshida K., Karin M. IKKalpha controls formation of the epidermis independently of NF-kappaB. Nature 2001; 410: 710–4
   PubMedGoogle Scholar
• Kere J., Srivastava A. K., Montonen O., Zonana J., Thomas N., Ferguson B., Munoz F., Morgan D., Clarke A., Baybayan P., Chen E. Y., Ezer S., Saarialho-Kere U., de la Chapelle A., Schlessinger D. X-linked anhidrotic (hypohidrotic) ectodermal dysplasia is caused by mutation in a novel transmembrane protein. Nat. Genet. 1996; 13: 409–16
   PubMed Web of Science ®Google Scholar
• Monreal A. W., Ferguson B. M., Headon D. J., Street S. L., Overbeek P. A., Zonana J. Mutations in the human homologue of mouse dl cause autosomal recessive and dominant hypohidrotic ectodermal dysplasia. Nat. Genet. 1999; 22: 366–9
   PubMed Web of Science ®Google Scholar
• Headon D. J., Emmal S. A., Ferguson B. M., Tucker A. S., Justice M. J., Sharpe P. T., Zonana J., Overbeek P. A. Gene defects in ectodermal dysplasia implicates a death domain adapter in development. Nature, 414: 913–6
   Google Scholar
• Yan M., Zhang Z., Brady J. R., Schilbach S., Fairbrother W. J., Dixit V. M. Identification of a novel death domain-containing adaptor molecule for ectodysplasin-A receptor that is mutated in crinkled mice. Curr. Biol. 2002; 12: 409–13
   PubMedGoogle Scholar
• Headon D. J., Overbeek P. A. Involvement of a novel Tnf receptor homologue in hair follicle induction. Nat. Genet. 1999; 22: 370–4
   PubMed Web of Science ®Google Scholar
• Srivastava A. K., Pispa J., Hartung A. J., Du Y., Ezer S., Jenks T., Shimada T., Pekkanen M., Mikkola M. L., Ko M. S., Thesleff I., Kere J., Schlessinger D. The Tabby phenotype is caused by mutation in a mouse homologue of the EDA gene that reveals novel mouse and human exons and encodes a protein (ectodysplasin-A) with collagenous domains. Proc. Natl. Acad. Sci. USA 1997; 94: 13069–74
   PubMed Web of Science ®Google Scholar
• Gugasyan R., Voss A., Varigos G., Thomas T., Grumont R. J., Kaur P., Grigoriadis G., Gerondakis S. The transcription factors c-rel and RelA control epidermal development and homeostasis in embryonic and adult skin via distinct mechanisms. Mol. Cell. Biol. 2004; 24: 5733–45
   PubMedGoogle Scholar
• Doffinger R., Smahi A., Bessia C., Geissmann F., Feinberg J., Durandy A., Bodemer C., Kenwrick S., Dupuis-Girod S., Blanche S., Wood P., Rabia S. H., Headon D. J., Overbeek P. A., Le Deist F., Holland S. M., Belani K., Kumararatne D. S., Fischer A., Shapiro R., Conley M. E., Reimund E., Kalhoff H., Abinun M., Munnich A., Israel A., Courtois G., Casanova J. L. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat. Genet. 2001; 27: 277–85
   PubMed Web of Science ®Google Scholar
• Jain A., Ma C. A., Liu S., Brown M., Cohen J., Strober W. Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nat. Immunol. 2001; 2: 223–8
   PubMed Web of Science ®Google Scholar
• Zonana J., Elder M. E., Schneider L. C., Orlow S. J., Moss C., Golabi M., Shapira S. K., Farndon P. A., Wara D. W., Emmal S. A., Ferguson B. M. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am. J. Hum. Genet. 2000; 67: 1555–62
   PubMed Web of Science ®Google Scholar
• Courtois G., Smahi A., Reichenbach J., Doffinger R., Cancrini C., Bonnet M., Puel A., Chable-Bessia C., Yamaoka S., Feinberg J., Dupuis-Girod S., Bodemer C., Livadiotti S., Novelli F., Rossi P., Fischer A., Israel A., Munnich A., Le Deist F., Casanova J. L. A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J. Clin. Invest. 2003; 112: 1108–15
   PubMed Web of Science ®Google Scholar
• Janssen R., van Wengen A., Hoeve M. A., ten Dam M., van der Burg M., van Dongen J., van de Vosse E., van Tol M., Bredius R., Ottenhoff T. H., Weemaes C., van Dissel J. T., Lankester A. The same IkappaBalpha mutation in two related individuals leads to completely different clinical syndromes. J. Exp. Med. 2004; 200: 559–68
   PubMedGoogle Scholar
• Kumar A., Eby M. T., Sinha S., Jasmin A., Chaudhary P. M. The ectodermal dysplasia receptor activates the nuclear factor-kappaB, JNK, and cell death pathways and binds to ectodysplasin A. J. Biol. Chem. 2001; 276: 2668–77
   Google Scholar
• Schmidt-Ullrich R., Aebischer T., Hulsken J., Birchmeier W., Klemm U., Scheidereit C. Requirement of NF-kappaB/Rel for the development of hair follicles and other epidermal appendices. Development 2001; 128: 3843–53
   PubMed Web of Science ®Google Scholar
• Schmidt-Ullrich R., Tobin D. J., Lenhard D., Schneider P., Paus R., Scheidereit C. NF-kappaB transmits Eda A1/EdaR signalling to activate Shh and cyclin D1 expression, and controls post-initiation hair placode down growth. Development 2006; 133: 1045–57
   Google Scholar
• Eby M. T., Jasmin A., Kumar A., Sharma K., Chaudhary P. M. TAJ, a novel member of the tumor necrosis factor receptor family, activates the c-Jun N-terminal kinase pathway and mediates caspase-independent cell death. J. Biol. Chem. 2000; 275: 15336–42
   PubMed Web of Science ®Google Scholar
• Yan M., Wang L. C., Hymowitz S. G., Schilbach S., Lee J., Goddard A., de Vos A. M., Gao W. Q., Dixit V. M. Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors. Science 2000; 290: 523–7
   PubMed Web of Science ®Google Scholar
• Naito A., Yoshida H., Nishioka E., Satoh M., Azuma S., Yamamoto T., Nishikawa S., Inoue J. TRAF6-deficient mice display hypohidrotic ectodermal dysplasia. Proc. Natl. Acad. Sci. USA 2002; 99: 8766–71
   PubMed Web of Science ®Google Scholar
• Morlon A., Munnich A., Smahi A. TAB2, TRAF6 and TAK1 are involved in NF-kappaB activation induced by the TNF-receptor, Edar and its adaptator Edaradd. Hum. Mol. Genet. 2005; 14: 3751–7
   PubMed Web of Science ®Google Scholar
• St-Jacques B., Dassule H. R., Karavanova I., Botchkarev V. A., Li J., Danielian P. S., McMahon J. A., Lewis P. M., Paus R., McMahon A. P. Sonic hedgehog signaling is essential for hair development. Curr. Biol. 1998; 8: 1058–68
   PubMed Web of Science ®Google Scholar
• Klement J. F., Rice N. R., Car B. D., Abbondanzo S. J., Powers G. D., Bhatt P. H., Chen C. H., Rosen C. A., Stewart C. L. IkappaBalpha deficiency results in a sustained NF-kappaB response and severe widespread dermatitis in mice. Mol. Cell. Biol. 1996; 16: 2341–9
   PubMed Web of Science ®Google Scholar
• Rebholz B., Haase I., Eckelt B., Paxian S., Flaig M. J., Ghoreschi K., Nedospasov S. A., Mailhammer R., Debey-Pascher S., Schultze J. L., Weindl G., Forster I., Huss R., Stratis A., Ruzicka T., Rocken M., Pfeffer K., Schmid R. M., Rupec R. A. Crosstalk between keratinocytes and adaptive immune cells in an IkappaBalpha protein-mediated inflammatory disease of the skin. Immunity 2007; 27: 296–307
   PubMed Web of Science ®Google Scholar
• Beg A. A., Sha W. C., Bronson R. T., Baltimore D. Constitutive NF-kappa B activation, enhanced granulopoiesis, and neonatal lethality in I kappa B alpha-deficient mice. Genes. Dev. 1995; 9: 2736–46
   PubMed Web of Science ®Google Scholar
• Ghoreschi K., Weigert C., Rocken M. Immunopathogenesis and role of T cells in psoriasis. Clin. Dermatol. 2007; 25: 574–80
   PubMed Web of Science ®Google Scholar
• Smahi A., Courtois G., Vabres P., Yamaoka S., Heuertz S., Munnich A., Israel A., Heiss N. S., Klauck S. M., Kioschis P., Wiemann S., Poustka A., Esposito T., Bardaro T., Gianfrancesco F., Ciccodicola A., D'Urso M., Woffendin H., Jakins T., Donnai D., Stewart H., Kenwrick S. J., Aradhya S., Yamagata T., Levy M., Lewis R. A., Nelson D. L. Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature 2000; 405: 466–72
   PubMed Web of Science ®Google Scholar
• Berlin A. L., Paller A. S., Chan L. S. Incontinentia pigmenti: a review and update on the molecular basis of pathophysiology. J. Am. Acad. Dermatol 2002; 47: 169–87, quiz 88–90
   PubMed Web of Science ®Google Scholar
• Makris C., Godfrey V. L., Krahn-Senftleben G., Takahashi T., Roberts J. L., Schwarz T., Feng L., Johnson R. S., Karin M. Female mice heterozygous for IKK gamma/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. Mol. Cell. 2000; 5: 969–79
   PubMedGoogle Scholar
• Schmidt-Supprian M., Bloch W., Courtois G., Addicks K., Israel A., Rajewsky K., Pasparakis M. NEMO/IKK gamma-deficient mice model incontinentia pigmenti. Mol. Cell. 2000; 5: 981–92
   PubMedGoogle Scholar
• Rudolph D., Yeh W. C., Wakeham A., Rudolph B., Nallainathan D., Potter J., Elia A. J., Mak T. W. Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice. Genes. Dev. 2000; 14: 854–62
   PubMed Web of Science ®Google Scholar
• Beg A. A., Sha W. C., Bronson R. T., Ghosh S., Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 1995; 376: 167–70
   PubMed Web of Science ®Google Scholar
• Li Z. W., Chu W., Hu Y., Delhase M., Deerinck T., Ellisman M., Johnson R., Karin M. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J. Exp. Med. 1999; 189: 1839–45
   PubMed Web of Science ®Google Scholar
• Tanaka M., Fuentes M. E., Yamaguchi K., Durnin M. H., Dalrymple S. A., Hardy K. L., Goeddel D. V. Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice. Immunity 1999; 10: 421–9
   PubMed Web of Science ®Google Scholar
• Lind M. H., Rozell B., Wallin R. P., van Hogerlinden M., Ljunggren H. G., Toftgard R., Sur I. Tumor necrosis factor receptor 1-mediated signaling is required for skin cancer development induced by NF-kappaB inhibition. Proc. Natl. Acad. Sci. USA 2004; 101: 4972–7
   PubMed Web of Science ®Google Scholar
• Pasparakis M., Courtois G., Hafner M., Schmidt-Supprian M., Nenci A., Toksoy A., Krampert M., Goebeler M., Gillitzer R., Israel A., Krieg T., Rajewsky K., Haase I. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 2002; 417: 861–6
   PubMed Web of Science ®Google Scholar
• van Hogerlinden M., Rozell B. L., Ahrlund-Richter L., Toftgard R. Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling. Cancer Res. 1999; 59: 3299–303
   PubMed Web of Science ®Google Scholar
• Nenci A., Huth M., Funteh A., Schmidt-Supprian M., Bloch W., Metzger D., Chambon P., Rajewsky K., Krieg T., Haase I., Pasparakis M. Skin lesion development in a mouse model of incontinentia pigmenti is triggered by NEMO deficiency in epidermal keratinocytes and requires TNF signaling. Hum. Mol. Genet. 2006; 15: 531–42
   Google Scholar
• Stratis A., Pasparakis M., Rupec R. A., Markur D., Hartmann K., Scharffetter-Kochanek K., Peters T., van Rooijen N., Krieg T., Haase I. Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J. Clin. Invest. 2006; 116: 2094–104
   PubMed Web of Science ®Google Scholar
• van Rooijen N., Bakker J., Sanders A. Transient suppression of macrophage functions by liposome-encapsulated drugs. Trends Biotechnol. 1997; 15: 178–85
   PubMed Web of Science ®Google Scholar
• Barton D., HogenEsch H., Weih F. Mice lacking the transcription factor RelB develop T cell-dependent skin lesions similar to human atopic dermatitis. Eur. J. Immunol. 2000; 30: 2323–32
   PubMed Web of Science ®Google Scholar
• Weih F., Carrasco D., Durham S. K., Barton D. S., Rizzo C. A., Ryseck R. P., Lira S. A., Bravo R. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell 1995; 80: 331–40
   PubMed Web of Science ®Google Scholar
• Weih F., Durham S. K., Barton D. S., Sha W. C., Baltimore D., Bravo R. Both multiorgan inflammation and myeloid hyperplasia in RelB-deficient mice are T cell dependent. J. Immunol. 1996; 157: 3974–9
   PubMedGoogle Scholar
• Weih F., Durham S. K., Barton D. S., Sha W. C., Baltimore D., Bravo R. p50-NF-kappaB complexes partially compensate for the absence of RelB: severely increased pathology in p50(−/−)relB(−/−) double-knockout mice. J. Exp. Med. 1997; 185: 1359–70
   PubMed Web of Science ®Google Scholar
• Kontgen F., Grumont R. J., Strasser A., Metcalf D., Li R., Tarlinton D., Gerondakis S. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes. Dev. 1995; 9: 1965–77
   PubMed Web of Science ®Google Scholar
• Sha W. C., Liou H. C., Tuomanen E. I., Baltimore D. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 1995; 80: 321–30
   PubMed Web of Science ®Google Scholar
• Delaney J. R., Mlodzik M. TGF-beta activated kinase-1: new insights into the diverse roles of TAK1 in development and immunity. Cell. Cycle. 2006; 5: 2852–5
   PubMed Web of Science ®Google Scholar
• Sato S., Sanjo H., Takeda K., Ninomiya-Tsuji J., Yamamoto M., Kawai T., Matsumoto K., Takeuchi O., Akira S. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat. Immunol. 2005; 6: 1087–95
   PubMed Web of Science ®Google Scholar
• Shim J. H., Xiao C., Paschal A. E., Bailey S. T., Rao P., Hayden M. S., Lee K. Y., Bussey C., Steckel M., Tanaka N., Yamada G., Akira S., Matsumoto K., Ghosh S. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes. Dev. 2005; 19: 2668–81
   PubMed Web of Science ®Google Scholar
• Omori E., Matsumoto K., Sanjo H., Sato S., Akira S., Smart R. C., Ninomiya-Tsuji J. TAK1 is a master regulator of epidermal homeostasis involving skin inflammation and apoptosis. J. Biol. Chem. 2006; 281: 19610–7
   PubMed Web of Science ®Google Scholar
• Kim J. Y., Omori E., Matsumoto K., Nunez G., Ninomiya-Tsuji J. TAK1 is a central mediator of NOD2 signaling in epidermal cells. J. Biol. Chem. 2008; 283: 137–44
   Google Scholar
• Zhang J. Y., Green C. L., Tao S., Khavari P. A. NF-kappaB RelA opposes epidermal proliferation driven by TNFR1 and JNK. Genes. Dev. 2004; 18: 17–22
   PubMed Web of Science ®Google Scholar
• Seitz C. S., Lin Q., Deng H., Khavari P. A. Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proc. Natl. Acad. Sci. USA 1998; 95: 2307–12
   PubMed Web of Science ®Google Scholar
• Stratis A., Pasparakis M., Markur D., Knaup R., Pofahl R., Metzger D., Chambon P., Krieg T., Haase I. Localized inflammatory skin disease following inducible ablation of I kappa B kinase 2 in murine epidermis. J. Invest. Dermatol. 2006; 126: 614–20
   Google Scholar
• Dajee M., Lazarov M., Zhang J. Y., Cai T., Green C. L., Russell A. J., Marinkovich M. P., Tao S., Lin Q., Kubo Y., Khavari P. A. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 2003; 421: 639–43
   PubMed Web of Science ®Google Scholar
• Zhang J. Y., Tao S., Kimmel R., Khavari P. A. CDK4 regulation by TNFR1 and JNK is required for NF-kappaB-mediated epidermal growth control. J. Cell. Biol. 2005; 168: 561–6
   PubMedGoogle Scholar
• Zhang J. Y., Adams A. E., Ridky T. W., Tao S., Khavari P. A. Tumor necrosis factor receptor 1/c-Jun-NH2-kinase signaling promotes human neoplasia. Cancer. Res. 2007; 67: 3827–34
   PubMed Web of Science ®Google Scholar
• van Hogerlinden M., Auer G., Toftgard R. Inhibition of Rel/Nuclear Factor-kappaB signaling in skin results in defective DNA damage-induced cell cycle arrest and Ha-ras- and p53-independent tumor development. Oncogene. 2002; 21: 4969–77
   Google Scholar
• Campbell C., Quinn A. G., Rees J. L. Codon 12 Harvey-ras mutations are rare events in non-melanoma human skin cancer. Br. J. Dermatol. 1993; 128: 111–4
   Google Scholar
• Rumsby G., Carter R. L., Gusterson B. A. Low incidence of ras oncogene activation in human squamous cell carcinomas. Br. J. Cancer. 1990; 61: 365–8
   PubMed Web of Science ®Google Scholar
• Abimelec P., Rybojad M., Cambiaghi S., Moraillon I., Cavelier-Balloy B., Marx C., Morel P. Late, painful, subungual hyperkeratosis in incontinentia pigmenti. Pediatr. Dermatol. 1995; 12: 340–2
   Google Scholar
• Adeniran A., Townsend P. L., Peachey R. D. Incontinentia pigmenti (Bloch-Sulzberger syndrome) manifesting as painful periungual and subungual tumours. J. Hand. Surg. [Br]. 1993; 18: 667–9
   Google Scholar
• Mascaro J. M., Palou J., Vives P. Painful subungual keratotic tumors in incontinentia pigmenti. J. Am. Acad. Dermatol. 1985; 13: 913–8
   Google Scholar
• Montes C. M., Maize J. C., Guerry-Force M. L. Incontinentia pigmenti with painful subungual tumors: a two-generation study. J. Am. Acad. Dermatol. 2004; 50: S45–52
   Google Scholar
• Sakai H., Minami M., Satoh E., Matsuo S., Iizuka H. Keratoacanthoma developing on a pigmented patch in incontinentia pigmenti. Dermatology. 2000; 200: 258–61
   Google Scholar
• Simmons D. A., Kegel M. F., Scher R. K., Hines Y. C. Subungual tumors in incontinentia pigmenti. Arch. Dermatol. 1986; 122: 1431–4
   Google Scholar
• Korstanje M. J., Bessems P. J. Incontinentia pigmenti with hyperkeratotic lesions in adulthood and possible squamous cell carcinoma. Dermatologica 1991; 183: 234–6
   Google Scholar
• Hartman D. L. Incontinentia pigmenti associated with subungual tumors. Arch. Dermatol. 1966; 94: 632–5
   Google Scholar
• Berg D., Otley C. C. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J. Am. Acad. Dermatol. 2002; 47: 1–17, quiz 8–20
   PubMed Web of Science ®Google Scholar
• Gangappa S., Kokko K. E., Carlson L. M., Gourley T., Newell K. A., Pearson T. C., Ahmed R., Larsen C. P. Immune responsiveness and protective immunity after transplantation. Transpl. Int. 2008; 21: 293–303
   PubMed Web of Science ®Google Scholar
• Brummelkamp T. R., Nijman S. M., Dirac A. M., Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 2003; 424: 797–801
   PubMed Web of Science ®Google Scholar
• Kovalenko A., Chable-Bessia C., Cantarella G., Israel A., Wallach D., Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003; 424: 801–5
   PubMed Web of Science ®Google Scholar
• Trompouki E., Hatzivassiliou E., Tsichritzis T., Farmer H., Ashworth A., Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003; 424: 793–6
   PubMed Web of Science ®Google Scholar
• Reiley W., Zhang M., Sun S. C. Negative regulation of JNK signaling by the tumor suppressor CYLD. J. Biol. Chem. 2004; 279: 55161–7
   PubMed Web of Science ®Google Scholar
• Massoumi R., Chmielarska K., Hennecke K., Pfeifer A., Fassler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 2006; 125: 665–77
   PubMed Web of Science ®Google Scholar
• Liu B., Park E., Zhu F., Bustos T., Liu J., Shen J., Fischer S. M., Hu Y. A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas. Proc. Natl. Acad. Sci. USA. 2006; 103: 17202–7
   Google Scholar
• Park E., Zhu F., Liu B., Xia X., Shen J., Bustos T., Fischer S. M., Hu Y. Reduction in IkappaB kinase alpha expression promotes the development of skin papillomas and carcinomas. Cancer. Res. 2007; 67: 9158–68
   Google Scholar